In a new agreement between Kezar Life Sciences and Everest Medicines, a new investigational therapy, zetomipzomib, for treatment of adults with active lupus nephritis, (LN, lupus-related kidney disease) will be developed, manufactured and marketed in Greater China, South Korea and Southeast Asia.
The two companies are working together in the PALIZADE study, a Phase 2B trial of zetomipzomib that is currently examining the therapy in 279 people with LN. One million people live in China with SLE lupus, and 40-60% have renal disease. Infection is highly prevalent in people with SLE in China and accounts for 65% of deaths. The collaboration will address a critical and unmet medical need for people with active LN in Asia.
Continue to follow the Lupus Foundation of America for updates on zetomipzomib as well as other lupus clinical trials. Learn more about medications used to treat lupus.
This post was originally published on this site